Description

QIAGEN N.V.: Expansion of Diagnostic & Life Sciences Portfolio & A Growing Global Footprint Are Key Growth Catalysts! 

QIAGEN’s second-quarter performance for 2025 reveals a mix of strategic progress and ongoing challenges reflecting the company’s adaptive strategies amid a volatile macroeconomic environment. With net sales increasing by 7% to $534 million, and a 6% growth at constant exchange rates (CER), the results underscore solid operational execution and a reinforcing commitment to its growth trajectory. However, it’s crucial to note that net sales growth includes significant contributions from ongoing core operations, while excluded discontinued product lines such as NeuMoDx and DIALUNOX.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!